Compelling Clinical and Economic Results in Scottish Pilot
| Stock | Painchek Ltd (PCK.ASX) |
|---|---|
| Release Time | 17 Sep 2025, 9:04 a.m. |
| Price Sensitive | Yes |
PainChek Delivers Compelling Clinical and Economic Benefits in Scottish Pilot
- Up to 40% reduction in falls
- Up to 27% reduction in dependency and care needs
- Significant improvements in clinical outcomes such as 25% reduction in analgesic usage and 33% reduction in antipsychotic prescriptions
PainChek Ltd, developer of the world's first smart device-based pain assessment and monitoring application, has announced the results of a successful pilot program in the Scottish care system. The independent evaluation, conducted by Edinburgh Napier University in collaboration with the Scottish Care Inspectorate, confirmed outstanding clinical benefits from the use of the PainChek Adult App. Key findings include up to 40% reduction in falls, up to 27% reduction in dependency and care needs, and significant improvements in clinical outcomes such as a 25% reduction in analgesic usage and a 33% reduction in antipsychotic prescriptions. The analysis also projected a potential £66 million (~A$134 million) saving in the Scottish healthcare system across 23,000 residents, delivering an estimated 10:1 return on investment. These results are now under review by the Scottish government as validation and support for expanding PainChek across Scotland's 38,000 aged care beds. PainChek's expansion in the UK market continues to gather momentum, with commercial licences covering more than 42,000 aged care beds across 1,000+ care homes. The successful completion of the InterSystems integration trial also enables seamless deployment across electronic care record platforms, unlocking further growth opportunities in the global hospital market.
The analysis estimates a ~£66 million cash-releasing benefit for Scotland Health based on implementing PainChek across 60% of Scottish care homes (representing approximately 23,000 residents) over five years.
PainChek is advanced in a number of new licence and global partnership opportunities and looks forward to updating the market in due course as further licences are secured. The Company is unable to provide an estimate for the additional revenue to be derived from these initiatives.